Journal Article

Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial

Isaacson, Stuart, Ballard, Clive, Corbett, Anne, Williams, Hilde, Dhall, Rohit, Mills, Roger, Chi-Burris, Kathy, Cummings, Jeffrey

2014

Overview

Parkinson's disease psychosis, which includes hallucinations and delusions, is frequent and debilitating in people with Parkinson's disease. We aimed to assess safety and efficacy of pimavanserin, a selective serotonin 5-HT2A inverse agonist, in this population. In our 6 week, randomised, double-blind, placebo-controlled study, we enrolled adults (aged ≥40 years) with Parkinson's disease psychosis. Antipsychotic treatments were not permitted during the study, but controlled antiparkinsonian medication or deep brain stimulation was allowed. Eligible participants entered a 2 week non-pharmacological lead-in phase to limit the placebo response, after which they were randomly allocated (1:1) to receive pimavanserin 40 mg per day or matched placebo. The primary outcome was antipsychotic benefit as assessed by central, independent raters with the Parkinson's disease-adapted scale for assessment of positive symptoms (SAPS-PD) in all patients who received at least one dose of study drug and had a SAPS assessment at baseline and at least one follow-up. We assessed safety and tolerability in all patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, number NCT01174004. Between Aug 11, 2010, and Aug 29, 2012, we randomly allocated 199 patients to treatment groups. For 90 recipients of placebo and 95 recipients of pimavanserin included in the primary analysis, pimavanserin was associated with a −5·79 decrease in SAPS-PD scores compared with −2·73 for placebo (difference −3·06, 95% CI −4·91 to −1·20; p=0·001; Cohen's d 0·50). Ten patients in the pimavanserin group discontinued because of an adverse event (four due to psychotic disorder or hallucination within 10 days of start of the study drug) compared with two in the placebo group. Overall, pimavanserin was well tolerated with no significant safety concerns or worsening of motor function. Pimavanserin may benefit patients with Parkinson's disease psychosis for whom few other treatment options exist. The trial design used in this study to manage placebo response could have applicability to other studies in neuropsychiatric disease. ACADIA Pharmaceuticals.

• Publisher: Elsevier Ltd,Elsevier,Elsevier Limited
• Subject: Adult and adolescent clinical studies / Aged / Alzheimer's disease / Analysis of Variance / Antiparkinson Agents - therapeutic use / Antipsychotic Agents - therapeutic use / Biological and medical sciences / Caregivers / Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases / Double-Blind Method / Drug dosages / Female / General aspects / Humans / Internal Medicine / Male / Medical sciences / Mental disorders / Metabolic disorders / Mortality / Neurology / Organic mental disorders. Neuropsychology / Parkinson Disease - drug therapy / Parkinson Disease - psychology / Parkinson's disease / Pharmaceuticals / Piperidines - therapeutic use / Psychology. Psychoanalysis. Psychiatry / Psychopathology. Psychiatry / Psychosis / Psychotic Disorders - drug therapy / Psychotropic drugs / Safety / Serotonin 5-HT2 Receptor Agonists - therapeutic use / Studies / Treatment Outcome / Urea - analogs & derivatives / Urea - therapeutic use